Pfizer Is Maintained at Buy by Guggenheim
Pfizer Analyst Ratings
Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Pfizer (PFE) Gets a Buy From Evercore ISI
Guggenheim Adjusts Price Target on Pfizer to $33 From $35, Keeps Buy Rating
Pfizer Analyst Ratings
B of A Securities Reinstates Neutral on Pfizer, Announces $29 Price Target
Berenberg Bank Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $29
Berenberg Bank Sticks to Their Hold Rating for Pfizer (PFE)
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It. -- Barrons.com
Wolfe Research Initiates Pfizer at Underperform With $25 Price Target
Pfizer Analyst Ratings
Wolfe Research Downgrades Pfizer(PFE.US) to Sell Rating, Announces Target Price $25
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
UBS Remains a Hold on Pfizer (PFE)
CFRA Upgrades Pfizer(PFE.US) to Buy Rating, Cuts Target Price to $30
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33